Latest News & Updates

Breaking News

  • 1 hour ago

  • Vaibhavi M.

IDEAYA Enrolls First Patient In Phase 1 Trial Of IDE034 Bispecific TOP1 Antibody-Drug Conjugate (ADC),Triggers $5M Biocytogen Milestone
Breaking News
Novartis To Establish Texas Radioligand Therapy Manufacturing Site, Expands Network With New Denton Facility

Vaibhavi M.

Hikma Launches Authorised Generic Version Of Nucynta In The US, Expands Generics Portfolio

Vaibhavi M.

FDA Approves Merck Animal Health’s NUMELVI For Canine Allergic Dermatitis, Atinvicitinib Becomes First Second-Gen JAK Inhibitor For Itch In Dogs

Vaibhavi M.

Plus Therapeutics Secures AMA Approval For New CPT Code Supporting REYOBIQ Delivery In CNS Cancers

Vaibhavi M.

Other trending news you may like to read

IDEAYA Enrolls First Patient In Phase 1 Trial Of IDE034 Bispecific TOP1 Antibody-Drug Conjugate (ADC),Triggers $5M Biocytogen Milestone

IDEAYA doses first patient in Phase 1 IDE034 bispecific TOP1 ADC trial.

Vaibhavi M.

Pharma Now

Novartis To Establish Texas Radioligand Therapy Manufacturing Site, Expands Network With New Denton Facility

Novartis to build Texas RLT plant, expanding US oncology manufacturing.

Vaibhavi M.

Pharma Now

Hikma Launches Authorised Generic Version Of Nucynta In The US, Expands Generics Portfolio

Hikma launches authorised generic Nucynta (tapentadol) in US pain market.

Vaibhavi M.

Pharma Now

FDA Approves Merck Animal Health’s NUMELVI For Canine Allergic Dermatitis, Atinvicitinib Becomes First Second-Gen JAK Inhibitor For Itch In Dogs

FDA clears NUMELVI, first second-gen JAK inhibitor for canine allergic itch.

Vaibhavi M.

Pharma Now